Literature DB >> 26917588

For glioma, a sweet side to diabetes.

Benjamin Purow1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26917588      PMCID： PMC4767247          DOI： 10.1093/neuonc/nov328

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  16 in total

1.  Pyruvate kinase M2 is a phosphotyrosine-binding protein.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Ning Wu; John M Asara; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

2.  Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.

Authors:  Ping Mao; Kaushal Joshi; Jianfeng Li; Sung-Hak Kim; Peipei Li; Lucas Santana-Santos; Soumya Luthra; Uma R Chandran; Panayiotis V Benos; Luke Smith; Maode Wang; Bo Hu; Shi-Yuan Cheng; Robert W Sobol; Ichiro Nakano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 3.  The ketogenic diet for the treatment of malignant glioma.

Authors:  Eric C Woolf; Adrienne C Scheck
Journal:  J Lipid Res       Date:  2014-02-06       Impact factor: 5.922

4.  Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?

Authors:  R E Kast; G Karpel-Massler; M-E Halatsch
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

5.  Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo.

Authors:  Isaac Marin-Valencia; Chendong Yang; Tomoyuki Mashimo; Steve Cho; Hyeonman Baek; Xiao-Li Yang; Kartik N Rajagopalan; Melissa Maddie; Vamsidhara Vemireddy; Zhenze Zhao; Ling Cai; Levi Good; Benjamin P Tu; Kimmo J Hatanpaa; Bruce E Mickey; José M Matés; Juan M Pascual; Elizabeth A Maher; Craig R Malloy; Ralph J Deberardinis; Robert M Bachoo
Journal:  Cell Metab       Date:  2012-06-06       Impact factor: 27.287

6.  Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme.

Authors:  Arnulf Mayer; Peter Vaupel; Hans-Garlich Struss; Alf Giese; Marcus Stockinger; Heinz Schmidberger
Journal:  Strahlenther Onkol       Date:  2014-06-18       Impact factor: 3.621

7.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

Authors:  Ryan J O Dowling; Mahvash Zakikhani; I George Fantus; Michael Pollak; Nahum Sonenberg
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

8.  Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study.

Authors:  A J Swerdlow; S P Laing; Z Qiao; S D Slater; A C Burden; J L Botha; N R Waugh; A D Morris; W Gatling; E A Gale; C C Patterson; H Keen
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

9.  The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma.

Authors:  Mohammed G Abdelwahab; Kathryn E Fenton; Mark C Preul; Jong M Rho; Andrew Lynch; Phillip Stafford; Adrienne C Scheck
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

10.  Personal history of diabetes, genetic susceptibility to diabetes, and risk of brain glioma: a pooled analysis of observational studies.

Authors:  Cari M Kitahara; Martha S Linet; Alina V Brenner; Sophia S Wang; Beatrice S Melin; Zhaoming Wang; Peter D Inskip; Laura E Beane Freeman; Melissa Z Braganza; Tania Carreón; Maria Feychting; J Michael Gaziano; Ulrike Peters; Mark P Purdue; Avima M Ruder; Howard D Sesso; Xiao-Ou Shu; Martha A Waters; Emily White; Wei Zheng; Robert N Hoover; Joseph F Fraumeni; Nilanjan Chatterjee; Meredith Yeager; Stephen J Chanock; Patricia Hartge; Preetha Rajaraman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254
View more
  3 in total

1.  Associations between prediagnostic blood glucose levels, diabetes, and glioma.

Authors:  Judith Schwartzbaum; Michael Edlinger; Victoria Zigmont; Pär Stattin; Grzegorz A Rempala; Gabriele Nagel; Niklas Hammar; Hanno Ulmer; Bernhard Föger; Göran Walldius; Jonas Manjer; Håkan Malmström; Maria Feychting
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

2.  Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.

Authors:  Alberto Azzalin; Giulia Nato; Elena Parmigiani; Francesca Garello; Annalisa Buffo; Lorenzo Magrassi
Journal:  Neoplasia       Date:  2017-03-19       Impact factor: 5.715

3.  Clinical Risk and Overall Survival in Patients with Diabetes Mellitus, Hyperglycemia and Glioblastoma Multiforme. A Review of the Current Literature.

Authors:  Nicola Montemurro; Paolo Perrini; Biagio Rapone
Journal:  Int J Environ Res Public Health       Date:  2020-11-17       Impact factor: 3.390
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.